The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 297.00
Bid: 290.00
Ask: 304.00
Change: 0.00 (0.00%)
Spread: 14.00 (4.828%)
Open: 297.00
High: 297.00
Low: 297.00
Prev. Close: 297.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HC Wainright & Co Virtual Conference Presentation

10 Sep 2020 07:00

RNS Number : 5403Y
MaxCyte, Inc.
10 September 2020
 

 

 

MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co

22nd Annual Global Investment Virtual Conference

 

 

GAITHERSBURG, MD, 10 September 2020 - MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020. Details are as follows:

 

Presentation Date/Time: Monday, September 14, at 4:00 p.m. EDT

Online access: https://wsw.com/webcast/hcw7/maxcyte/2019107

 

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .

 

 

Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden

 

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 

 

+44 (0)20 7260 1000

 

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Ashley Tapp

 

--------------------------------------------------------------

 

+44 (0)203 709 5700

maxcyte@consilium-com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAKKCBNOBKDBCK
Date   Source Headline
11th Nov 20217:00 amRNSMaxCyte Reports Third Quarter Financial Results
3rd Nov 20211:00 pmRNSAppointment of Chairman of the Board
29th Oct 20215:01 pmRNSResult of AGM
28th Oct 20213:00 pmRNSLicense with Nkarta, Inc.
26th Oct 20217:00 amRNSNotice of Results
6th Oct 20217:00 amRNSHoldings in Company
1st Oct 20213:49 pmRNSNotice of AGM and Change of Director
1st Oct 202112:36 pmRNSTotal Voting Rights
17th Sep 20212:35 pmRNSMaxCyte Set to Join Russell 2000® Index
14th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSFiling of Form 10-Q
2nd Sep 20212:26 pmRNSNotice of Results
10th Aug 20217:00 amRNSGrant of Options
9th Aug 20217:00 amRNSLicense with Sana Biotechnology
5th Aug 20214:05 pmRNSAmendments to Bylaws
3rd Aug 20213:51 pmRNSClosing of Offering
2nd Aug 20217:00 amRNSFull Exercise of Over-Allotment Option
30th Jul 20214:43 pmRNSSecond Price Monitoring Extn
30th Jul 20214:36 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSPricing of Offering and Approval to List on Nasdaq
26th Jul 202111:14 amRNSLaunch of Offering and Application to List
19th Jul 202112:30 pmRNSTermination of DI facility and transition to CDI
12th Jul 20217:00 amRNSS-1 Financial information & Directorate Change
12th Jul 20217:00 amRNSPublic Filing of Registration Statement with SEC
6th Jul 20215:36 pmRNSResult of Special Meeting
16th Jun 20217:01 amRNSPublication of Annual Report and Accounts
16th Jun 20217:00 amRNSStockholder Circular and Notice of Special Meeting
15th Jun 20217:00 amRNSMaxcyte Appoints Two New Non-Executive Directors
2nd Jun 20219:18 amRNSTotal Voting Rights
25th May 20217:00 amRNSSigning of Strategic Platform Licence
14th May 20217:00 amRNSProposed Dual-Listing on Nasdaq
13th May 20217:00 amRNSConsolidation of Trading Lines
20th Apr 20217:00 amRNSFull Year Results
15th Apr 20217:00 amRNSNotice of Full Year Results
1st Apr 20217:00 amRNSTotal Voting Rights
11th Mar 20213:01 pmRNSHolding(s) in Company
3rd Mar 20217:00 amRNSTotal Voting Rights
23rd Feb 20217:00 amRNSParticipation in Upcoming Investor Conferences
19th Feb 20217:00 amRNSDirector Dealings and Issue of Equity
17th Feb 20215:44 pmRNSGrant of Options
15th Feb 20214:32 pmRNSHolding(s) in Company
12th Feb 20211:59 pmRNSHolding(s) in Company
8th Feb 20212:59 pmRNSHolding(s) in Company
5th Feb 20219:01 amRNSPrice Monitoring Extension
4th Feb 20217:00 amRNSDirector Dealings and Issue of Equity
4th Feb 20217:00 amRNSCORRECTION: MaxCyte Announces £40m Subscription
3rd Feb 20214:36 pmRNSMaxCyte Announces £40 million Subscription
3rd Feb 20214:35 pmRNSAppointment of Joint Corporate Broker
21st Jan 20212:49 pmRNSIncrease to Block Listing
20th Jan 20217:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.